Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data from the I-SPY2 Randomized Clinical Trial

W. Fraser Symmans, Christina Yau, Yunn Yi Chen, Ron Balassanian, Molly E. Klein, Lajos Pusztai, Rita Nanda, Barbara A. Parker, Brian Datnow, Gregor Krings, Shi Wei, Michael D. Feldman, Xiuzhen Duan, Beiyun Chen, Husain Sattar, Laila Khazai, Jay C. Zeck, Sharon Sams, Paulette Mhawech-Fauceglia, Mara RendiSunati Sahoo, Idris Tolgay Ocal, Fang Fan, Lauren Grasso Lebeau, Tuyethoa Vinh, Megan L. Troxell, A. Jo Chien, Anne M. Wallace, Andres Forero-Torres, Erin Ellis, Kathy S. Albain, Rashmi K. Murthy, Judy C. Boughey, Minetta C. Liu, Barbara B. Haley, Anthony D. Elias, Amy S. Clark, Kathleen Kemmer, Claudine Isaacs, Julie E. Lang, Hyo S. Han, Kirsten Edmiston, Rebecca K. Viscusi, Donald W. Northfelt, Qamar J. Khan, Brian Leyland-Jones, Sara J. Venters, Sonal Shad, Jeffrey B. Matthews, Smita M. Asare, Meredith Buxton, Adam L. Asare, Hope S. Rugo, Richard B. Schwab, Teresa Helsten, Nola M. Hylton, Laura Van 'T Veer, Jane Perlmutter, Angela M. Demichele, Douglas Yee, Donald A. Berry, Laura J. Esserman

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data from the I-SPY2 Randomized Clinical Trial

Fingerprint

Medicine & Life Sciences